作者投稿
专家审稿
编辑办公
邮件订阅
RSS
-
摘要: 抗缪勒管激素(anti-Müllerian hormone, AMH)是由女性卵泡颗粒细胞和男性睾丸支持细胞分泌的二聚体糖蛋白, 可抑制女性卵泡的募集和生长, 调节男性睾丸间质细胞的功能。目前文章多阐述其临床应用:检测血清AMH的水平可用于评估卵巢储备, 预测辅助生殖过程中的卵巢反应, 评估肿瘤患者卵巢储备, 辅助诊断多囊卵巢综合征、卵巢早衰及预测绝经等, 但对其检测方法和参考区间研究阐述较少。近年来, 随着AMH检测技术的发展, 临床应用领域越来越广泛, 本文就AMH的生理、临床应用、检测方法和参考区间等问题进行深入探讨。Abstract: Anti-Müllerian hormone(AMH) is a dimeric glycoprotein secreted by follicular granulosa cell and sertoli cell. AMH inhibits the recruitment and growth of follicles in female, and adjusts the function of leydig cells in male. Serum AMH level is a potential marker for ovarian reserve. At present, the article elaborated its clinical application:the level of serum AMH can be used to evaluate ovarian reserve, to predict ovarian response during assisted reproductive process, to evaluate ovarian reserve of cancer patients, to diagnose polycystic ovary syndrome, premature ovarian failure and predictive menopause. There are few studies on the detection methods and reference intervals. With the development of detection technology, AMH has become more widely used in clinical medicine. The physiology, clinical application, assay methods and reference intervals of AMH are discussed in this article.
-
[1] Wilson CA, di Clemente N, Ehrenfels C, et al. Müllerian inhibiting substance requires its N-terminal domain for maintenance of biological activity, a novel finding within the transforming growth factor-beta superfamily[J]. Mol Endocrinol, 1993, 7:247-257. https://www.ncbi.nlm.nih.gov/pubmed/8469238 [2] Di Clemente N, Wilson C, Faure E, et al. Cloning, expression and alternative splicing of the receptor for anti-Müllerian hormone[J]. Mol Endocrinol, 1994, 8:1006-1020. https://www.ncbi.nlm.nih.gov/pubmed/7997230 [3] Jamil Z, Fatima SS, Ahmed K, et al. Anti-Müllerian hormone:above and beyond conventional ovarian reserve markers[J]. Dis Markers, 2016:5246217. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4764725/ [4] Matzuk MM, Lamb DJ. The biology of infertility:research advances and clinical challenges[J]. Nat Med, 2008, 14:1197-1213. doi: 10.1038/nm.f.1895 [5] Josso N, Rey RA, Picard JY. Anti-Müllerian hormone:a valuable addition to the toolbox of the pediatric endocrinologist[J]. Int J Endocrinol, 2013, 2013:674105. https://www.researchgate.net/profile/Rodolfo_Rey/publication/259560314_Anti-Mullerian_Hormone_A_Valuable_Addition_to_the_Toolbox_of_the_Pediatric_Endocrinologist/links/0046353bd3195d1680000000/Anti-Muellerian-Hormone-A-Valuable-Addition-to-the-Toolbox-of-the-Pediatric-Endocrinologist.pdf [6] Lee MM, Donahoe PK. Müllerian inhibiting substance:a gonadal hormone with multiple functions[J]. Endocr Rev, 1993, 14:152-164. https://www.sciencedirect.com/science/article/pii/S0015028297814173 [7] Weenen C, Laven JS, Von Bergh AR, et al. Anti-Müllerian hormone expression pattern in the human ovary:potential implications for initial and cyclic follicle recruitment[J]. Mol Hum Reprod, 2004, 10:77-83. doi: 10.1093/molehr/gah015 [8] Kelsey TW, Wright P, Nelson SM, et al. A validated model of serum anti-müllerian hormone from conception to menopause[J]. PLoS One, 2011, 16:e22024. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=Open J-Gate000003875995 [9] Broekmans FJ, Visser JA, Laven JS, et al. Anti-Müllerian hormone and ovarian dysfunction[J]. Trends Endocrinol Metab, 2008, 19:340-347. doi: 10.1016/j.tem.2008.08.002 [10] Seifer DB, Maclaughlin DT. Müllerian inhibiting substance is an ovarian growth factor of emerging clinical significance[J]. Fertil Steril, 2007, 88:539-546. doi: 10.1016/j.fertnstert.2007.02.014 [11] Rosen MP, Johnstone E, McCulloch CE, et al. A characterization of the relationship of ovarian reserve markers with age[J]. Fertil Steril, 2012, 97:238-243. doi: 10.1016/j.fertnstert.2011.10.031 [12] La Marca A, Giulini S, Tirelli A, et al. Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology[J]. Hum Reprod, 2006, 22:766-771. https://www.ncbi.nlm.nih.gov/pubmed/17071823 [13] Koninger A, Koch L, Enekwe A, et al. Change of anti-Müllerian hormone levels during follicular phase in PCOS patients[J]. Gynecol Endocrinol, 2015, 31:26-30. doi: 10.3109/09513590.2014.959436 [14] Fanchin R, Taieb J, Lozano DH, et al. High reproducibility of serum anti-Müllerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status[J]. Hum Reprod, 2005, 20:923-927. doi: 10.1093/humrep/deh688 [15] Mertens AC, Yong J, Dietz AC, et al. Conditional survival in pediatric malignancies:analysis of data from the Childhood Cancer Survivor Study and the Surveillance, Epidemiology, and End Results Program[J]. Cancer, 2015, 121:1108-1117. doi: 10.1002/cncr.29170 [16] Barnabei A, Strigari L, Marchetti P, et al. Predicting ovarian activity in women affected by early breast cancer:A Meta-analysis-based nomogram[J]. Oncologist, 2015, 20:1111-1118. doi: 10.1634/theoncologist.2015-0183 [17] Iwase A, Nakamura T, Nakahara T, et al. Assessment of ovarian reserve using anti-Müllerian hormone levels in benign gynecologic conditions and surgical interventions:a systematic narrative review[J]. Reprod Biol Endocrinol, 2014, 12:125. doi: 10.1186/1477-7827-12-125 [18] Henry NL, Xia R, Schott AF, et al. Prediction of postchemotherapy ovarian function using markers of ovarian reserve[J]. The Oncologist, 2014, 19:68-74. doi: 10.1634/theoncologist.2013-0145 [19] Anderson RA, Rosendahl M, Kelsey TW, et al. Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer[J]. European Journal of Cancer, 2013, 49:3404-3411. doi: 10.1016/j.ejca.2013.07.014 [20] Iwase A, Nakamura T, Nakahara T, et al. Anti-Mullerian hormone and assessment of ovarian reserve after ovarian toxic treatment:a systematic narrative review[J]. Reprod Sci, 2015, 22:519-526. doi: 10.1177/1933719114549856 [21] Nelson SM, Yates RW, Lyall H, et al. Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception[J]. Hum Reprod, 2009, 24:867-875. https://academic.oup.com/humrep/article/24/4/867/632894 [22] Broer SL, van Disseldorp J, Broeze KA, et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy:an individual patient data approach[J]. Hum Reprod Update, 2013, 19:26-36. doi: 10.1093/humupd/dms041 [23] Broer SL, Dolleman M, van Disseldorp J, et al. Prediction of an excessive response in in vitro fertilization from patient cha-racteristics and ovarian reserve tests and comparison in subgroups:an individual patient data meta-analysis[J]. Fertil Steril, 2013, 100:420-429. doi: 10.1016/j.fertnstert.2013.04.024 [24] Li R, Gong F, Zhu Y, et al. Anti-Müllerian hormone for prediction of ovarian response in Chinese infertile women undergoing IVF/ICSI cycles:a prospective, multi-centre, observational study[J]. Reprod Bio Med Online, 2016, 33:506-512. doi: 10.1016/j.rbmo.2016.07.003 [25] Nelson SM, Klein BM, Arce J C. Comparison of anti Müllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials[J]. Fertil Steril, 2015, 103:923-930. doi: 10.1016/j.fertnstert.2014.12.114 [26] La Marca A, Sunkara SK. Individualization of controlled ova-rian stimulation in IVF using ovarian reserve markers:from theory to practice[J]. Hum Reprod Update, 2014, 20:124-140. doi: 10.1093/humupd/dmt037 [27] Toner JP, Seifer DB. Why we may abandon basal follicle-stimulating hormone testing:a sea change in determining ovarian reserve using anti-müllerian hormone[J]. Fertil Steril, 2013, 99:1825-1830. doi: 10.1016/j.fertnstert.2013.03.001 [28] Dewailly D.Diagnostic criteria for PCOS:Is there a need for a rethink?[J]. Best Pract Res Clin Obstet Gynaecol, 2016, 37:5-11. doi: 10.1016/j.bpobgyn.2016.03.009 [29] Laven JS, Mulders AG, Visser JA, et al. Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age[J]. J Clin Endocrinol Metab, 2004, 89:318-323. doi: 10.1210/jc.2003-030932 [30] Das M, Gillott DJ, Saridogan E, et al. Anti-Müllerian hormone is increased in follicular fluid from unstimulated ovaries in women with polycystic ovary syndrome[J]. Hum Reprod, 2008, 23:2122-2126. doi: 10.1093/humrep/den185 [31] Tal R, Seifer DB, Khanimov M, et al. Characterization of women with elevated antimüllerian hormone levels(AMH):correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes[J]. Am J Obstet Gynecol, 2014, 211:59, e1-e8. https://www.ncbi.nlm.nih.gov/pubmed/24593938 [32] Iliodromiti S, Kelsey TW, Anderson RA, et al. Can anti-Müllerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data[J]. J Clin Endocrinol Metab, 2013, 98:3332-3340. doi: 10.1210/jc.2013-1393 [33] Broer SL, Eijkemans MJ, Scheffer GJ, et al. Anti-müllerian hormone predicts menopause:a long-term follow-up study in normoovulatory women[J]. J Clin Endocrinol Metab, 2011, 96:2532-2539. doi: 10.1210/jc.2010-2776 [34] Dolleman M, Depmann M, Eijkemans MJ, et al. Anti-Müllerian hormone is a more accurate predictor of individual time to menopause than mother's age at menopause[J]. Hum Reprod, 2014, 29:584-591. doi: 10.1093/humrep/det446 [35] Dolleman M, Verschuren WM, Eijkemans MJ, et al. Added value of anti-Müllerian hormone in prediction of menopause:results from a large prospective cohort study[J]. Hum Reprod, 2015, 30:1974-1981. doi: 10.1093/humrep/dev145 [36] Knauff EA, Eijkemans MJ, Lambalk CB, et al. Anti-Müllerian hormone, inhibin B, and antral follicle count in young women with ovarian failure[J]. J Clin Endocrinol Metab, 2009, 94:786-792. doi: 10.1210/jc.2008-1818 [37] La Marca A, Volpe A. The Anti-Müllerian hormone and ova-rian cancer[J]. Hum Reprod Update, 2007, 13:265-273. doi: 10.1093/humupd/dml060 [38] Farkkila A, Koskela S, Bryk S, et al. The clinical utility of serum anti-Müllerian hormone in the follow-up of ovarian adult-type granulosa cell tumors-a comparative study with inhibin B[J]. Int J Cancer, 2015, 137:1661-1671. doi: 10.1002/ijc.29532 [39] Rey RA, Lhommé C, Marcillac I, et al. Anti-müllerian hormone as a serum marker of granulosa cell tumorsof the ovary:comparative study with serum alpha-inhibin and estradiol[J]. Am J Obstet Gynecol, 1996, 174:958-965. doi: 10.1016/S0002-9378(96)70333-2 [40] Josso N, Rey RA, Picard JY. Anti-müllerian hormone:a valuable addition to the toolbox of the pediatric endocrinologist[J]. Int J Endocrinol, 2013:674105. https://www.hindawi.com/journals/ije/2013/674105/fig1/ [41] Aksglaede. 2014 AUA Guideline[S]. 2010. [42] Pearson K, Long M, Prasad J, et al. Assessment of the Access AMH assay as an automated, high-performance replacement for the AMH Generation Ⅱ manual ELISA[J]. Reprod Biol Endocrinol, 2016, 14:8. doi: 10.1186/s12958-016-0143-3 [43] Nelson SM, Pastuszek E, Kloss G, et al. Two new automated, compared with two enzyme-linked immunosorbent, antimüllerian hormone assays[J]. Fertil Steril, 2015, 104:1016-1021. doi: 10.1016/j.fertnstert.2015.06.024 [44] Abma JC, Chandra A, Mosher WD, et al. Fertility, family planning, and women's health:new data from the 1995 National Survey of Family Growth[J]. Vital and Health Statistics, 1997, 19:1-114. http://cn.bing.com/academic/profile?id=b3a9874513a1e1c7fee09ba68960bf14&encoded=0&v=paper_preview&mkt=zh-cn [45] Bleil ME, Gregorich SE, Adler NE, et al. Race/ethnic disparities in reproductive age:an examination of ovarian reserve estimates across four race/ethnic groups of healthy, regularly cycling women[J]. Fertil Steril, 2014, 101:199-207. doi: 10.1016/j.fertnstert.2013.09.015 [46] Du X, Ding T, Zhang H, et al.Age-specific normal reference range for serum anti-müllerian hormone in healthy chinese han women:a nationwide population-based study[J]. Reprod Sci, 2016, 23:1019-1027. doi: 10.1177/1933719115625843 -
下载:
点击查看大图
图(1)
计量
- 文章访问数: 153
- HTML全文浏览量: 131
- PDF下载量: 22
- 被引次数: 0
